Waters’ (WAT) “Hold” Rating Reiterated at Barclays

Waters (NYSE:WAT)‘s stock had its “hold” rating reiterated by Barclays in a note issued to investors on Monday. They presently have a $202.00 target price on the medical instruments supplier’s stock. Barclays’ target price would indicate a potential downside of 0.11% from the company’s current price.

Several other research analysts have also commented on WAT. Evercore ISI began coverage on Waters in a research report on Wednesday, January 3rd. They issued an “in-line” rating and a $198.00 price objective on the stock. BTIG Research began coverage on Waters in a research report on Friday. They issued a “buy” rating and a $230.00 price objective on the stock. Zacks Investment Research lowered Waters from a “buy” rating to a “hold” rating in a research report on Saturday. Goldman Sachs Group began coverage on Waters in a research report on Tuesday, September 26th. They issued a “hold” rating and a $180.00 price objective on the stock. Finally, Citigroup reissued a “neutral” rating and issued a $180.00 price objective on shares of Waters in a research report on Wednesday, October 25th. Eleven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $197.33.

Waters (NYSE:WAT) opened at $202.23 on Monday. The company has a debt-to-equity ratio of 0.66, a current ratio of 6.16 and a quick ratio of 5.71. Waters has a 52-week low of $136.14 and a 52-week high of $202.85. The company has a market capitalization of $16,083.96, a PE ratio of 29.83, a price-to-earnings-growth ratio of 2.71 and a beta of 0.82.

Waters (NYSE:WAT) last released its quarterly earnings data on Tuesday, October 24th. The medical instruments supplier reported $1.77 EPS for the quarter, beating the consensus estimate of $1.74 by $0.03. Waters had a return on equity of 23.61% and a net margin of 24.34%. The company had revenue of $565.58 million for the quarter, compared to analyst estimates of $555.25 million. During the same period last year, the company posted $1.57 earnings per share. The firm’s revenue was up 7.4% compared to the same quarter last year. equities research analysts anticipate that Waters will post 7.42 EPS for the current fiscal year.

In other news, Director William J. Miller sold 3,500 shares of Waters stock in a transaction dated Tuesday, December 5th. The stock was sold at an average price of $194.94, for a total transaction of $682,290.00. Following the sale, the director now directly owns 25,849 shares of the company’s stock, valued at $5,039,004.06. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Rohit Khanna sold 26,913 shares of Waters stock in a transaction dated Friday, October 27th. The stock was sold at an average price of $197.93, for a total value of $5,326,890.09. Following the sale, the senior vice president now directly owns 13,677 shares in the company, valued at $2,707,088.61. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 93,159 shares of company stock worth $18,412,172. Corporate insiders own 5.07% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Pensionfund Sabic bought a new stake in Waters in the fourth quarter valued at about $1,546,000. Pensionfund DSM Netherlands bought a new stake in Waters in the fourth quarter valued at about $3,091,000. Parametric Portfolio Associates LLC increased its holdings in Waters by 6.4% in the third quarter. Parametric Portfolio Associates LLC now owns 166,698 shares of the medical instruments supplier’s stock valued at $29,926,000 after buying an additional 10,015 shares during the last quarter. IFM Investors Pty Ltd bought a new stake in Waters in the third quarter valued at about $398,000. Finally, Bares Capital Management Inc. increased its holdings in Waters by 0.6% in the third quarter. Bares Capital Management Inc. now owns 728,948 shares of the medical instruments supplier’s stock valued at $130,861,000 after buying an additional 4,663 shares during the last quarter. 92.12% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.com-unik.info/2018/01/08/waters-wat-hold-rating-reiterated-at-barclays.html.

About Waters

Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans.

Analyst Recommendations for Waters (NYSE:WAT)

What are top analysts saying about Waters? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Waters and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit